A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Springdale, Arkansas.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT07518186
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JNJ-79635322 — DRUG
    JNJ-79635322 will be administered as SC injection.
  • Teclistamab — DRUG
    Teclistamab will be administered as SC injection.

Study Details

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

Key Dates

Start date
May 31, 2026
Status verified
Jun 2026
Primary completion
Apr 29, 2029
Completion
Dec 8, 2032

Study Design

Enrollment
700 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: JNJ-79635322
    Participants will receive subcutaneous (SC) dose of JNJ-79635322 treatment of a finite duration or intolerable toxicity (whichever is first).
  • Active Comparator: Arm B: Teclistamab
    Participants will receive teclistamab as a SC injection until PD or intolerable toxicity.

Primary Outcome Measure

Complete Response (CR) or Better [ Time Frame: Up to approximately 41 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Highlands Oncology GroupSpringdaleArkansas72762-
Nebraska Cancer SpecialistsOmahaNebraska68130-

Find similar trials in Springdale, AR

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Highlands Oncology Group· Springdale, ARNebraska Cancer Specialists· Omaha, NE

Related Studies